Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

The Bausch and Lomb Center honors two significant figures in the history of RIT; John J. Bausch and Captain Henry Lomb. With the outbreak of the Civil War in 1861, Henry Lomb enlisted with the ...

Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Bausch & Lomb Corp.’s stock soared 10% early Wednesday ... Growth was driven by higher sales of Lumify eye drops, Eye Vitamins and Dry Eye Portfolio in the consumer eye-care business and higher ...

City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial ...